AI-driven quality standardisation of IHC


About the webinar

Immunohistochemistry stain quality remains a significant unmet need for diagnostic labs. Data from NordiQC shows that over 30% of labs fail EQA proficiency testing for the general module and around 20% of labs fail for the breast panel. To address that, Visiopharm has developed Qualitopix which allows labs to quantitatively track stain quality variation over time using AI to complement EQA proficiency testing runs. In this workshop, Visiopharm will present a case study of a high volume, European lab using Qualitopix to identify a series of root cause issues with their staining instruments. We will also discuss our collaboration with UK Neqas and provide a demo of the platform.

Meet the Host

Martin Kristensson

Senior VP, Global Clinical Sales | Visiopharm

Senior Vice President, Global Clinical Sales Martin Kristensson is responsible for our global clinical commercial activities and teams. Together with his team, he coordinated the development of Visiopharms clinical products, and the change management processes used to implement the tools in the daily clinical routine across Denmark. In close collaboration with colleagues and customers, he continues to investigate new applications of image analysis within pathology, pursuing new ways of offering standardized high-quality data and diagnosis.

He received his M.Sc. in Biomedical Engineering from the Technical University of Denmark in 2011, specializing in Signal and Model-based Diagnostics, combined with Image Diagnostics and Radiation Physics. In 2014, he became a certified Project Manager.

Andrew Dodson

Director | UK NEQAS Immunocytochemistry and In Situ Hybridisation (ICC & ISH)

Andrew Dodson has been a Member of the Board of Assessors since 1995: became Deputy Director for the Scheme in 2007. Worked within the NHS since 1981, qualifying as a Biomedical Scientist in Histopathology while working at St. George's Hospital in London in 1984. Moved to Liverpool in 1990 and ran the Immunocytochemistry service and latterly the Molecular Pathology service at the Royal Liverpool University Hospital until 2013.

Returned to London to take up a role as a Senior Research Clinical Scientist in the Breast Cancer Research Unit at the Royal Marsden Hospital. Took post as Deputy Director UK NEQAS Immunocytochemistry and In Situ Hybridisation (ICC & ISH) in 2007. At the end of 2018, was appointed as its Director.